|
|
| Research article summary (published 27 Feb 2006): |
Clinical pharmacokinetics of anti-angiogenic photodynamic therapy with benzoporphyrin derivative monoacid ring-A in dogs having naturally occurring neoplasms.
Full Abstract
The aim of this study was to examine the pharmacokinetics of clinically applied benzoporphyrin derivative monoacid ring-A (BPD-MA; Verteporfin), a second-generation photosensitizer, during a trial of photodynamic therapy (PDT) in nine dogs having naturally occurring neoplasms. After injecting BPD-MA at 0.5 mg/kg intravenously, its mean half-life (t1/2) was found to be 8.14 +/- 5.34 h, mean clearance (Cl) 35.13 +/- 9.62 ml/(h kg), the mean value of the volume of distribution (Vc) 0.08 +/- 0.01 l/kg and the mean steady state volume of distribution (Vss) 0.38 +/- 0.31 l/kg respectively. With the exception of a transitional increase in serum alkaline phosphatase activity, no other clinical abnormalities were observed. The t1/2 in dogs with naturally occurring tumours was longer than that in humans, but similar to that in rats. The values of Cl and Vss in dogs having naturally occurring neoplasms were lower than those in humans. It is suggested that the pharmacokinetics of BPD-MA in tumour-bearing dogs would be helpful in determining the protocol of a short drug-light interval PDT with BPD-MA that mainly targets the tumour vasculature.
Author information
Author/s: Osaki, T (T); Hoshino, S (S); Hoshino, Y (Y); Takagi, S (S); Okumura, M (M); Kadosawa, T (T); Fujinaga, T (T);
Affiliation: Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060 0818, Hokkaido, Japan. ohchan(-atsign-)vetmed.hokudai.ac.jp
Journal and publication information
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal: Journal of veterinary medicine. A, Physiology, pathology, clinical medicine (J Vet Med A Physiol Pathol Clin Med), published in Germany. (Language: eng)
Reference: 2006-Mar; vol 53 (issue 2) : pp 108-12
Dates: Created 2006/02/09; Completed 2006/06/08; Revised 2006/11/15;
PMID: 16466464, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Photodynamic therapy for companion animals with cancer.
29 Apr 2002 - Photodynamic therapy for prostatic carcinoma in a dog.
27 Feb 2003 - Fluorescence detection of a new photosensitizer, PAD-S31, in tumour tissues and its use as a photodynamic treatment for skin tumours in dogs and a cat: a preliminary report.
29 Apr 2004 - Fighting cancer in dogs. Morris Animal Foundation leads campaign to find cures.
29 Apr 2007 - Porphyrins as radiosensitizing agents for solid neoplasms.
30 Dec 2002 - Photodynamic therapy: clinical experience at the Department of Radiotherapy at Padova General Hospital.
29 Sep 1991 - Cancer researchers usher in dog days of medicine.
29 Sep 2005 - Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity.
13 Apr 2000 - The impact of pharmacokinetics on cancer chemotherapy.
30 Oct 1988 - Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
16 Dec 2001
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.